Tuberculosis (TB) is one of the world’s most common and life threatening diseases, with over 95% of TB deaths occurring in low- and middle-income countries (WHO, 2020). Some estimates indicate that one third of the world's population is infected with TB.

In 2018, an estimated 10 million people were diagnosed with TB worldwide. Many people remain undiagnosed and untreated; vulnerable populations, including children, the poor, and people living with HIV, are at greatest risk for being undiagnosed. Treating TB is possible, but it is difficult and requires long courses of multiple antibiotics. For the 500,000 people who develop multidrug-resistant TB (MDRTB) annually, treatment is more complicated. The second-line drugs used are expensive, hard to access, and often bring painful side effects.

In spite of these challenges, an estimated 58 million lives were saved through TB diagnosis and treatment between 2000 and 2018.

As the procurement agent for the Global Drug Facility (GDF), IDA has supplied first- and second-line anti-TB drugs to over 100 countries. Our TB range isn’t limited to medicines. We also supply laboratory equipment for diagnosis and products for patients with HIV/TB coinfection.

For more information about our TB activities and products, download our

TB Product Factsheet

In November 2017, 75 ministers agreed to take urgent action to end TB by 2030. The Moscow Declaration to End TB is focused on health systems strengthening, increased financing, research and development, and improved accountability. Further progress on this commitment was made at the 2018 UN High-Level Meeting on TB. The milestones for 2020 are a 35% reduction in number of TB deaths and a 20% reduction in TB incidence rate. Furthermore, no TB households should face catastrophic costs as a result of TB burden by 2020.